Literature DB >> 9294619

Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide.

W Bloch1, T Klotz, C Loch, G Schmidt, U Engelmann, K Addicks.   

Abstract

BACKGROUND: Nitric oxide (NO) is suggested as a mediator involved in the regulation of smooth muscle tone, blood flow, and secretory function of the genitourinary tract and originates from different NO synthase (NOS) isoforms located in endothelial, neuronal, and epithelial structures. The aim of the present study was to determine the location of endothelial and neuronal NOS in the human prostate.
METHODS: Histochemical NADPH-diaphorase (NADPH-d) staining, ultrastructural NADPH examination, and NOS immunohistochemistry were performed on histologically verified nonmalignant prostate tissue from normal nonobstructive and hyperplastic obstructive human prostates.
RESULTS: In the prostatic tissue, NADPH-d staining and immunohistochemistry with bNOS antibody revealed the existence of a dense nitrinergic innervation of glandular epithelium, fibromuscular stroma, and blood vessels. NADPH-d reaction in glandular epithelium was not confirmed by ecNOS or bNOS immunohistochemistry. In benign prostatic hyperplasia (BPH), the nitrinergic innervation is reduced. The vascular distribution of ecNOS provides evidence for a segmental differentiation of the NO-mediated vascular regulation.
CONCLUSIONS: NO plays an important role in the autonomic innervation of all compartments of prostatic tissue. In obstructive BPH, the nitrinergic innervation is reduced compared to that in normal prostate tissue. Further studies are necessary to elucidate the complex role of NO in the prostate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294619     DOI: 10.1002/(sici)1097-0045(19970915)33:1<1::aid-pros1>3.0.co;2-p

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  28 in total

Review 1.  Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.

Authors:  Stefan Uckert; Christian G Stief; Margit Mayer; Udo Jonas; Petter Hedlund
Journal:  World J Urol       Date:  2005-12-06       Impact factor: 4.226

2.  Medical therapy for benign prostatic hyperplasia: new terminology, new concepts, better choices.

Authors:  Steven A Kaplan
Journal:  Rev Urol       Date:  2006

3.  Sexual Function and alpha-Blockers.

Authors:  Kevin T McVary
Journal:  Rev Urol       Date:  2005

4.  [Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study].

Authors:  S Uckert; K Sigl; E S Waldkirch; P Sandner; E Ulbrich; M Oelke; C G Stief; M A Kuczyk
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

Review 5.  The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Casey Lythgoe; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

6.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

Review 7.  The Complex Relationship Between Lower Urinary Tract Symptoms and Sexual Health.

Authors:  Hanson Zhao; Howard H Kim
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

8.  Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.

Authors:  Alex Gomelsky; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

9.  Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate.

Authors:  Stephan Buse; Christian Gilfrich; Gencay Hatiboglu; Johannes Huber; Jens Bedke; Jesco Pfitzenmaier; Axel Haferkamp; Markus Hohenfellner
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

10.  Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.

Authors:  Dong Soo Park; Taek Woo Cho; Yong Kyu Lee; Young Tae Lee; Young Kwon Hong; Woong Ki Jang
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.